Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Competition In Prostate Cancer? Medivation’s Enzalutamide Now With FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Medivation and Astellas have submitted their castration-resistant prostate cancer drug enzalutamide to FDA and hope to gain priority review for the long-anticipated therapy.

You may also be interested in...



Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC

The most recent events in the fast-evolving castration-resistant prostate cancer field illustrate how the major advances in therapy for patients who failed chemotherapy are now spreading to the larger population of CRPC patients receiving first-line therapy for metastatic disease. The upcoming year should see Phase III results from candidates ranging from a kinase inhibitor to an antisense agent.

HHS OIG To Investigate Drug Shortages, Rebates, Other Pharma Issues In 2013

A number of topical issues will be investigated by the HHS Office of Inspector General, according to its work plan for fiscal year 2013. Pharma industry issues are concentrated in the Medicare and Medicaid space.

At Astellas R&D Day, Enzalutamide And In-house Tech In The Spotlight

Astellas has tried to build oncology knowhow in the past six years, and while licensed compounds approach approval, Phase II in-house compounds may show whether it can be a global leader.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel